Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):312-320. doi: 10.2176/nmc.ra.2016-0312. Epub 2017 May 1.

Abstract

Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: 11C-methionine (MET), 11C-choline, and 18F-fluorodeoxyglucose. These studies included aspects such as tumor behavior, diagnosis, grade of malignancy, spread and invasion, viability, and genetic deletions; moreover, they also evaluated PET as a tool for planning radiation therapy (RT) and determining its outcome. MET-PET in particular is considered to be the most informative for diagnosis and therapeutic decision-making for glioma patients; it is therefore considered crucial for brain tumor therapy. MET-PET is expected to be widely used for brain tumor patients going forward.

Keywords: choline; fluorodeoxyglucose; glioma; methionine; positron emission tomography.

Publication types

  • Review

MeSH terms

  • Central Nervous System Neoplasms / diagnostic imaging*
  • Central Nervous System Neoplasms / pathology
  • Central Nervous System Neoplasms / therapy
  • Glioma / diagnostic imaging*
  • Glioma / pathology
  • Glioma / therapy
  • Humans
  • Positron-Emission Tomography*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals